Skip to content
mapperlab
← Dashboard
Stock

EVH

Evolent Health, Inc.
Latest close $3.905 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
5
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
2

Marquee-fund ownership over time

Aug 13, 2021Aug 14, 2024Aug 14, 2025May 15, 2026
Now
8

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Maverick Capital re-entered$28$3.90-86%
Citadel Advisors$27$3.90-85%
Millennium Management re-entered$27$3.90-85%
AQR Capital Management$13$3.90-69%
Two Sigma Investments$8.82$3.90-56%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management 2× in & out→ $3.96-5%
Renaissance Technologies→ $4.10-1%
D.E. Shaw 3× in & out—+0%
Bridgewater Associates→ $8.94-63%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Evolent Health, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
9
Filings · last 90d
9
Total on file
369
Recent SEC buffer
Most recent
Jun 8, 2026

30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 369 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Evolent Health, Inc.

Annual figures sourced directly from Evolent Health, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$1.88B
FY2025+291% YoY
Net income
-$534.51M
FY2025-500%+ YoY
EPS (diluted)
$-5.07
FY2025-500%+ YoY
Free cash flow(?)
$38.84M
FY2025+107% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Evolent Health, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ4 2025Q1 2026$0.00—+0%
Millennium ManagementQ4 2025open$0.00—+0%
Point72 Asset ManagementQ4 2025Q2 2026$4.18$3.96-5%
Renaissance TechnologiesQ4 2025Q2 2026$4.16$4.10-1%
Maverick CapitalQ3 2025open$8.82$4.00-55%
Two Sigma InvestmentsQ2 2025open$8.82$3.90-56%
D.E. ShawQ2 2025open$0.00—+0%
D.E. ShawQ1 2025open$10$3.90-61%
AQR Capital ManagementQ4 2024open$13$3.90-69%
Citadel AdvisorsQ3 2024open$27$3.90-85%
Millennium ManagementQ3 2024open$27$3.90-85%
Point72 Asset ManagementQ3 2024Q3 2025$27$8.82-67%
Maverick CapitalQ2 2023Q3 2023$35$28-19%
Maverick CapitalQ4 2021Q1 2022$28$23-15%
Bridgewater AssociatesQ3 2021Q2 2025$24$8.94-63%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.